UNIVERSITY OF SOUTH CAROLINA · COLLEGE OF
NURSING
NURS 711
Pharmacotherapies
FINAL PRACTICE EXAMINATION · 2026 update
2026 Edition — Independent study and review resource. Not affiliated with or endorsed by the University of South Carolina.
,NURS 711 Pharmacotherapies | Final Practice Examination (2026)
UNIVERSITY OF SOUTH CAROLINA | COLLEGE OF NURSING
Final Practice Examination
NURS 711 - Pharmacotherapies | 2026 Edition
This practice examination contains 100 multiple-choice items calibrated to graduate advanced practice (APRN)
pharmacotherapeutics. Read each stem carefully, select the single best answer (A-D), and review the verified answer and
rationale that follow each item. Coverage spans prescribing principles, antimicrobial, cardiovascular, endocrine,
psychotropic, pain, respiratory, gastrointestinal, and geriatric pharmacotherapy, with special-population and safety items
interspersed throughout.
1. A 62-year-old woman with epilepsy has been maintained on phenytoin with a
therapeutic serum level. Her neurologist increases the daily dose slightly, and a
repeat level drawn one week later is markedly elevated, with the patient reporting
nystagmus and ataxia. Which pharmacokinetic principle best explains this finding?
A. Phenytoin switches from first-order to zero-order elimination at
therapeutic concentrations, so small dose increases produce
disproportionate rises in serum level.
B. Phenytoin induces its own metabolism, so levels rise progressively over time
regardless of dose.
C. Phenytoin has a very large volume of distribution, so serum levels always lag
behind dose changes by several weeks.
D. Phenytoin is eliminated primarily by renal excretion, so levels rise
whenever the glomerular filtration rate declines.
Correct Answer: A
Rationale: Phenytoin exhibits saturable, capacity-limited (zero-order) metabolism
because the enzymes responsible for its hydroxylation become saturated within the
therapeutic range. Once saturation occurs, small dose increments can produce large,
nonlinear increases in serum concentration and toxicity such as nystagmus and
ataxia. The other choices misstate the drug's kinetics: autoinduction, delayed
distribution, and renal elimination are not the mechanism.
2. A patient stabilized on warfarin is started on a new medication, and within
days the INR rises sharply. The new drug is also highly protein bound. What
is the most likely pharmacokinetic explanation?
2026 Edition - 100 Questions with Verified Answers and Rationales Page 1 of 38
,NURS 711 Pharmacotherapies | Final Practice Examination (2026)
A. The new drug increases warfarin absorption from the gastrointestinal tract.
B. The new drug reduces the volume of distribution of warfarin,
requiring a permanent dose reduction of about 50 percent.
C. Displacement of warfarin from plasma albumin binding sites transiently
increases the free (active) fraction, adding to any inhibition of warfarin
metabolism.
D. Albumin displacement permanently increases warfarin clearance, so the
INR rise is laboratory error.
2026 Edition - 100 Questions with Verified Answers and Rationales Page 2 of 38
, NURS 711 Pharmacotherapies | Final Practice Examination (2026)
Correct Answer: C
Rationale: Warfarin is approximately 99 percent protein bound; coadministration
of another highly bound drug can displace it and transiently raise the free fraction,
which is clinically important because warfarin has a narrow therapeutic index. In
practice, the sustained INR rise usually reflects added inhibition of CYP2C9
metabolism by the interacting drug. Displacement alone does not permanently
change clearance or require fixed dose reduction.
3. A patient begins a drug with a half-life of 24 hours taken once daily.
Approximately how long will it take to reach steady-state plasma concentrations if
the dose is unchanged?
A. 12 to 24 hours
B. 2 to 3 days
C. 4 to 5 days
D. 10 to 14 days
Correct Answer: C
Rationale: Steady state is reached after approximately 4 to 5 half-lives regardless
of dose frequency. For a drug with a 24-hour half-life, this equals roughly 4 to 5
days of consistent dosing. The 10-to-14-day estimate would apply only to a drug
with a half-life of about 2 to 3 days.
4. A patient with stable angina uses sublingual nitroglycerin rather than an
oral tablet for acute episodes. What is the pharmacokinetic advantage of the
sublingual route for this drug?
A. Sublingual administration increases the half-life of nitroglycerin, allowing less
frequent dosing.
B. Sublingual administration bypasses first-pass hepatic metabolism,
delivering therapeutic plasma concentrations that oral dosing cannot achieve
reliably.
C. Sublingual administration eliminates the need for dose adjustment in renal
impairment, which oral nitroglycerin requires.
D. Sublingual administration converts nitroglycerin to its active metabolite
more rapidly than any other route.
2026 Edition - 100 Questions with Verified Answers and Rationales Page 3 of 38
NURSING
NURS 711
Pharmacotherapies
FINAL PRACTICE EXAMINATION · 2026 update
2026 Edition — Independent study and review resource. Not affiliated with or endorsed by the University of South Carolina.
,NURS 711 Pharmacotherapies | Final Practice Examination (2026)
UNIVERSITY OF SOUTH CAROLINA | COLLEGE OF NURSING
Final Practice Examination
NURS 711 - Pharmacotherapies | 2026 Edition
This practice examination contains 100 multiple-choice items calibrated to graduate advanced practice (APRN)
pharmacotherapeutics. Read each stem carefully, select the single best answer (A-D), and review the verified answer and
rationale that follow each item. Coverage spans prescribing principles, antimicrobial, cardiovascular, endocrine,
psychotropic, pain, respiratory, gastrointestinal, and geriatric pharmacotherapy, with special-population and safety items
interspersed throughout.
1. A 62-year-old woman with epilepsy has been maintained on phenytoin with a
therapeutic serum level. Her neurologist increases the daily dose slightly, and a
repeat level drawn one week later is markedly elevated, with the patient reporting
nystagmus and ataxia. Which pharmacokinetic principle best explains this finding?
A. Phenytoin switches from first-order to zero-order elimination at
therapeutic concentrations, so small dose increases produce
disproportionate rises in serum level.
B. Phenytoin induces its own metabolism, so levels rise progressively over time
regardless of dose.
C. Phenytoin has a very large volume of distribution, so serum levels always lag
behind dose changes by several weeks.
D. Phenytoin is eliminated primarily by renal excretion, so levels rise
whenever the glomerular filtration rate declines.
Correct Answer: A
Rationale: Phenytoin exhibits saturable, capacity-limited (zero-order) metabolism
because the enzymes responsible for its hydroxylation become saturated within the
therapeutic range. Once saturation occurs, small dose increments can produce large,
nonlinear increases in serum concentration and toxicity such as nystagmus and
ataxia. The other choices misstate the drug's kinetics: autoinduction, delayed
distribution, and renal elimination are not the mechanism.
2. A patient stabilized on warfarin is started on a new medication, and within
days the INR rises sharply. The new drug is also highly protein bound. What
is the most likely pharmacokinetic explanation?
2026 Edition - 100 Questions with Verified Answers and Rationales Page 1 of 38
,NURS 711 Pharmacotherapies | Final Practice Examination (2026)
A. The new drug increases warfarin absorption from the gastrointestinal tract.
B. The new drug reduces the volume of distribution of warfarin,
requiring a permanent dose reduction of about 50 percent.
C. Displacement of warfarin from plasma albumin binding sites transiently
increases the free (active) fraction, adding to any inhibition of warfarin
metabolism.
D. Albumin displacement permanently increases warfarin clearance, so the
INR rise is laboratory error.
2026 Edition - 100 Questions with Verified Answers and Rationales Page 2 of 38
, NURS 711 Pharmacotherapies | Final Practice Examination (2026)
Correct Answer: C
Rationale: Warfarin is approximately 99 percent protein bound; coadministration
of another highly bound drug can displace it and transiently raise the free fraction,
which is clinically important because warfarin has a narrow therapeutic index. In
practice, the sustained INR rise usually reflects added inhibition of CYP2C9
metabolism by the interacting drug. Displacement alone does not permanently
change clearance or require fixed dose reduction.
3. A patient begins a drug with a half-life of 24 hours taken once daily.
Approximately how long will it take to reach steady-state plasma concentrations if
the dose is unchanged?
A. 12 to 24 hours
B. 2 to 3 days
C. 4 to 5 days
D. 10 to 14 days
Correct Answer: C
Rationale: Steady state is reached after approximately 4 to 5 half-lives regardless
of dose frequency. For a drug with a 24-hour half-life, this equals roughly 4 to 5
days of consistent dosing. The 10-to-14-day estimate would apply only to a drug
with a half-life of about 2 to 3 days.
4. A patient with stable angina uses sublingual nitroglycerin rather than an
oral tablet for acute episodes. What is the pharmacokinetic advantage of the
sublingual route for this drug?
A. Sublingual administration increases the half-life of nitroglycerin, allowing less
frequent dosing.
B. Sublingual administration bypasses first-pass hepatic metabolism,
delivering therapeutic plasma concentrations that oral dosing cannot achieve
reliably.
C. Sublingual administration eliminates the need for dose adjustment in renal
impairment, which oral nitroglycerin requires.
D. Sublingual administration converts nitroglycerin to its active metabolite
more rapidly than any other route.
2026 Edition - 100 Questions with Verified Answers and Rationales Page 3 of 38
